...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Increase in Incidence of Medically Treated Thyroid Disease in Children With Down Syndrome After Rerelease of American Academy of Pediatrics Health Supervision Guidelines
【24h】

Increase in Incidence of Medically Treated Thyroid Disease in Children With Down Syndrome After Rerelease of American Academy of Pediatrics Health Supervision Guidelines

机译:《美国儿科学会健康监督指南》重新发布后,唐氏综合症患儿的药物治疗的甲状腺疾病发生率增加

获取原文
           

摘要

OBJECTIVE. The purpose of this work was to estimate the incidence of medically treated thyroid disease in children with Down syndrome enrolled in Tennessee Medicaid (TennCare) during 1995–2005 and to determine whether rates increased after rerelease of American Academy of Pediatrics guidelines in 2001.PATIENTS AND METHODS. We conducted a population-based retrospective cohort study in which we identified children with Down syndrome by using TennCare files and birth certificates. We included 1- to 18-year-olds who were continuously enrolled in TennCare and did not fill a prescription for thyroid medication during a 90-day prestudy period. The rate of medically treated thyroid disease (prescription filled for thyroid medication) was the main outcome. We used Poisson regression to estimate rates of medically treated thyroid disease according to study year, age, gender, race, region of residence, and payer type.RESULTS. During the 11-year study period, 1257 children with Down syndrome (28% black, 72% white) met inclusion criteria. Overall, 10.8% filled a new prescription for thyroid medication. Rates of medically treated thyroid disease per 1000 child-years were 13.25 (1995–1997), 13.34 (1998–1999), 13.62 (2000–2001), 22.37 (2002–2003), and 22.51 (2004–2005). After adjusting for child age and race, there was an increased rate of medically treated thyroid disease in 2002–2003 and 2004–2005 compared with 1995–1997. In a comparison cohort of children without Down syndrome, there was a smaller increase in the rate of medically treated thyroid disease when comparing 2002–2003 and 2004–2005 with 1995–1997.CONCLUSIONS. Over the 11-year period, 10.8% of children with Down syndrome filled a new prescription for a thyroid medication. A 73% increase in the incidence of medically treated thyroid disease occurred after rerelease of American Academy of Pediatrics guidelines, which may have influenced screening.
机译:目的。这项工作的目的是评估1995-2005年在田纳西州医疗补助计划(TennCare)入选的唐氏综合症患儿接受药物治疗的甲状腺疾病的发生率,并确定在2001年美国儿科学会指南重新发布后,其发病率是否增加。方法。我们进行了一项基于人群的回顾性队列研究,其中我们通过使用TennCare文件和出生证明来识别患有唐氏综合症的儿童。我们纳入了1到18岁的儿童,他们不断地参加TennCare,并且在90天的研究期间未填写甲状腺药物处方。主要的结果是药物治疗的甲状腺疾病(甲状腺药物处方)的发生率。根据研究年份,年龄,性别,种族,居住地区和付款人类型,我们使用Poisson回归来估计药物治疗的甲状腺疾病的发生率。在为期11年的研究中,有1257名唐氏综合症儿童(黑人28%,白人72%)符合纳入标准。总体而言,有10.8%的人开了甲状腺药物的新处方。每1000个儿童年的治疗甲状腺疾病比率为13.25(1995-1997),13.34(1998-1999),13.62(2000-2001),22.37(2002-2003)和22.51(2004-2005)。在调整了孩子的年龄和种族之后,与1995-1997年相比,2002-2003年和2004-2005年甲状腺药物治疗的比率有所增加。在没有唐氏综合症的儿童的比较队列中,将2002-2003年和2004-2005年与1995-1997年进行比较,药物治疗的甲状腺疾病的发病率增幅较小。结论。在这11年中,唐氏综合症儿童的10.8%填写了新的甲状腺药物处方。重新发布美国儿科学会指南后,药物治疗的甲状腺疾病的发生率增加了73%,这可能影响了筛查。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号